Received tentative approval from the FDA for YUTREPIA™ (treprostinil) inhalation powder for both pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung ...

The study demonstrates that activating the vitamin D receptor (VDR) with calcitriol suppresses cell proliferation in ...

Medical Dialogues presents a rare disease series, delving into the realm of uncommon medical conditions. Rare diseases are ...

Another is producing a market-leading treatment for pulmonary arterial hypertension. But their appeal isn’t tethered to the ...

Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia – – Topline data from 1-year open-label extension (OLE) trial now expected in December 2024 – ...

Liquidia LQDA is gearing up to announce its quarterly earnings on Wednesday, 2024-11-13. Here's a quick overview of what ...

Preclinical Development Updates F230: F230 is a selective endothelin receptor agonist for the treatment of pulmonary arterial hypertension ("PAH”). In May 2024, Gyre Pharmaceuticals received NMPA ...

Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis ...

Sit-stand desks reduce sitting but don’t lower blood pressure, and prolonged standing without movement may harm ...

Orchestra Biomed Holdings, Inc. is a biomedical innovation company that partners with leading medical device companies to develop and commercialize high-impact healthcare technologies, focusing on ...

NEW HOPE, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact ...

The Australian Cardiovascular Alliance (ACvA) has received vital Federal funding to advance its innovative national approach addressing cardiovascular ...